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ABSTRACT
Contemporary tissue engineered skeletal muscle models display a high degree of physiological accuracy compared with native tissue, and
therefore may be excellent platforms to understand how various pathologies affect skeletal muscle. Chronic obstructive pulmonary disease
(COPD) is a lung disease which causes tissue hypoxia and is characterized bymuscle ﬁber atrophy and impaired muscle function. In the present
study we exposed engineered skeletal muscle to varying levels of oxygen (O2; 21–1%) for 24 h in order to see if a COPD like muscle phenotype
could be recreated in vitro, and if so, at what degree of hypoxia this occurred.Maximal contractile forcewas attenuated in hypoxia compared to
21% O2; with culture at 5% and 1% O2 causing the most pronounced effects with 62% and 56% decrements in force, respectively. Furthermore
at these levels of O2, myotubes within the engineered muscles displayed signiﬁcant atrophy which was not seen at higher O2 levels. At the
molecular level we observed increases inmRNA expression ofMuRF-1 only at 1%O2whereasMAFbx expressionwas elevated at 10%, 5%, and
1% O2. In addition, p70S6 kinase phosphorylation (a downstream effector of mTORC1) was reduced when engineered muscle was cultured at
1% O2, with no signiﬁcant changes seen above this O2 level. Overall, these data suggest that engineered muscle exposed to O2 levels of 5%
adapts in a manner similar to that seen in COPD patients, and thus may provide a novel model for further understanding muscle wasting
associated with tissue hypoxia. J. Cell. Biochem. 118: 2599–2605, 2017. © 2017 The Authors. Journal of Cellular Biochemistry Published by Wiley
Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
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T issue engineered skeletal muscle shows excellent structuraland functional similarities to in vivo tissue [Cheng et al., 2014],
with a variety of published models capable of generating aligned
myotubes surrounded by biologically relevant matrices, and able to
produce contractile force. As such, engineered skeletal muscle
models are proving useful tools for physiological investigations
concerned with muscle adaptation [Khodabukus and Baar, 2015;
Khodabukus et al., 2015], and may also have utility in furthering our
understanding of diseases characterized by alterations in muscle
phenotype. However, at present there is little data concerning the
manipulation of engineered muscle to replicate diseased tissue.
Chronic obstructive pulmonary disease (COPD) is a lung disease
which leads to a reduction in tissue oxygenation and therefore a state of
tissue hypoxia. Skeletal muscle of COPD patients is characterized by
reduced ﬁber size compared to healthy individuals (muscle atrophy),
and a reduction inmuscle strength [Mador and Bozkanat, 2001], which
ultimately increases morbidity and mortality in these individuals
[Swallow et al., 2007]. The loss ofmuscle size is likely due to alterations
in molecular pathways which regulate muscle growth and breakdown.
The mTORC1 signaling pathway is a well characterized anabolic
pathway which is activated in skeletal muscle by nutrients, growth
factors, and muscle loading [Kimball, 2014], resulting in increased
mRNA translational capacity and thereforemuscle growth. Conversely,
the ubiquitin proteasome system is a catabolic pathway, which is
heavily implicated in the loss of skeletalmuscle size in scenarios such as
disuse and disease [Bodine et al., 2001; Lecker et al., 2004], and the two
E3 ubiquitin ligases Muscle Ring Finger 1 (MuRF-1) and Muscle
Atrophy F-box (MAFbx) have been shown to induce muscle atrophy
when overexpressed or prevent atrophy when knocked out using
animal and cell culture models [Bodine et al., 2001]. Skeletal muscle of
COPD patients has been reported to express elevated levels of MuRF-1
and MAFbx, and reductions in mTORC1 signaling proteins such as
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p70S6 kinase and 4EBP-1 [Favier et al., 2010], and thus both reductions
in protein synthesis and increases in protein breakdown likely drive the
loss of muscle size in this disease state.
While individuals suffering from COPD display severe tissue
hypoxia, they also exhibit systemic inﬂammation [Takabatake et al.,
2000], negative energy balance [Vermeeren et al., 1997], and
oxidative stress [Rahman et al., 1996], which are all confounding
factors which may contribute to the muscle atrophy observed in this
population. However, there is a growing body of literature to suggest
that hypoxia itself acts as a stimulus formuscle atrophy. For example,
de Theije et al. exposed rats to step wise reductions in oxygen (O2)
levels and found signiﬁcant reductions in muscle size which were
greater than those observed in a pair fed group designed to account for
the reductions in appetite associatedwith hypoxia. This loss ofmuscle
mass was also associated acutely with reduced p70S6 kinase
phosphorylation, and chronically with sustained elevations in
MuRF-1 and MAFbx mRNA levels [de Theije et al., 2013]. Similarly,
in vitro studies have observed loss of cell size when myotubes are
exposed to lowO2 conditions [Caron et al., 2009], and impairedmuscle
regenerationwhen cells differentiate in hypoxia [Di Carlo et al., 2004;
Yun et al., 2005]; an effect alsomirrored in vivo [Chaillou et al., 2014].
Human skeletal muscle normally experiences O2 tension of
approximately 35mmHg [Richardson et al., 2006] or 5% O2, which
is considered physiological tissue hypoxia, and thus in pathological
hypoxia such as that associated with COPD O2 levels are further
reduced in comparison. In vitro however, cells are routinely cultured
at 21% O2, and therefore in comparison any reductions in O2 levels
below this may be sensed by the cells as a hypoxic stimulus. The
majority of skeletal muscle in vitro investigations to date have
deliveredhypoxia in the region of 1–5%O2 [Chakravarthy et al., 2001;
Di Carlo et al., 2004; Yun et al., 2005; Caron et al., 2009; Martin et al.,
2009; Li et al., 2011; Liu et al., 2012], thus spanning the physiological/
pathological hypoxia spectrum. However, the effect of varying O2
concentrations on skeletalmuscle size and function, and the inﬂuence
on catabolic/anabolic signaling pathways has not yet been explored.
In the present investigation, we therefore, cultured tissue engineered
skeletal muscle acutely (24 h) under varying levels of hypoxia, and
sought to determine whether; (i) engineered muscle responds to
reductions in %O2 in a similar manner to skeletal muscle (i.e., atrophy)
and thereforemayprovide ausefulmodel of hypoxia associated skeletal
muscle disease, and (ii) atwhat%O2 the loss ofmuscle size and function
is apparent.We hypothesized that a step wise reduction inmuscle force
and atrophy would be observed as the %O2 was reduced below 21%
since cells in culture would view this as a hypoxic stimulus. We also
predicted that these phenotypic observations would be underpinned by
increases inmarkers of ubiquitin proteasome activity anda reduction in
mTORC1 signaling.
METHODOLOGY
CELL CULTURE
C2C12murinemyoblasts (ECACC, Sigma–Aldrich, UK)were used for all
experimentation, and cultured in T80 ﬂasks (NuncTM, Fisher Scientiﬁc,
UK) maintained in a humidiﬁed 5% CO2 incubator (HERAcell 240i,
Thermo Fisher, UK). Cells were maintained in growth media (GM)
consisting of high glucose DMEM (Fisher Scientiﬁc, UK) supplemented
with 20% FBS (Dutscher Scientiﬁc, UK), 100U/ml penicillin, and
100mg/ml streptomycin (Fisher Scientiﬁc) until 80% conﬂuent, at
which point cells were enzymatically detached from the ﬂasks with
Trypsin-EDTA and counted using the trypan blue exclusion method.
Thereafter cells were either re-plated for further subculture, or used for
experimentation. All experiments were conducted using cells which
had undergone fewer than 10 passages since receipt.
TISSUE ENGINEERING SKELETAL MUSCLE AND EXPERIMENTAL
DESIGN
Engineeredmuscle constructs were fabricated as previously described
[Martin et al., 2015]. Brieﬂy, two6mmsutureswere pinned intoPDMS
(Sylgard 184 Elastomer, Dow Corning, UK) coated 35mm plates
12mm apart using 0.15mm minutien pins (Entomoravia, Czech
Republic). Plates were sterilized using ultraviolet light and washing
with 70% ethanol and subsequently left to dry for 3 h. Each plate then
received 500ml of GM containing 10U/ml thrombin (Sigma–Aldrich)
and 80mg/ml aprotinin (Sigma–Aldrich) which was spread evenly
over the surface of the plate ensuring that the sutures were fully
covered. 200ml of 20mg/ml stock ﬁbrinogen (Sigma–Aldrich)
solution was then added to the plate, and was agitated gently to
ensure even distribution and then left to incubate for 10min at room
temperature before being transferred to the incubator (37°C) for 1 h.
Thereafter, 1 105 C2C12myoblasts were seeded on to the surface of
the construct in GM supplemented with 0.25mg/ml 6-aminocaproic
acid (Sigma–Aldrich) which was replaced daily for the ﬁrst 4 days of
the culture period. On day 4, GM was replaced with Differentiation
media (DM) consisting of high glucose DMEM supplemented with 2%
horse serum (Sigma–Aldrich), 100U/ml penicillin, and 100mg/ml
streptomycin and 0.5mg/ml 6-aminocaproic acid. Following 2 days
in DM, the media was changed to maintenance media (MM)
containing 7% FBS (Dutscher Scientiﬁc) in order to help prevent
excessiveﬁbrin degradation [Khodabukus andBaar, 2009],whichwas
replaced daily for the remainder of the culture period. At day 13,
following media replenishment constructs were exposed to either
relative hypoxia (1%, 5%, 10%, or 15% O2) or normoxia (21% O2) for
the ﬁnal 24h of the culture period (see Fig. 1). To achieve this,
normoxic constructs were returned back to the standard incubator
while hypoxic constructs were transferred to a separate incubator
where the O2 levels can be altered through the addition of nitrogen gas
(MCO-5M, Sanyo, UK).
ASSESSMENT OF MUSCLE FUNCTION
To determine if hypoxia could impact uponmaximal skeletal muscle
force production, after 24 h of exposure constructs were removed
from the respective condition, washed once in a krebs ringer HEPES
buffer (KRH; 10mM HEPES, 138mM NaCl, 4.7mM KCl, 1.25mM
CaCl2, 1.25mMMgSO4, 5mMGlucose, 0.05% bovine serum albumin
in dH20) and attached to a model 403A Aurora force transducer
(Aurora Scientiﬁc, UK). Following the addition of 4ml of KRH buffer,
stainless steel electrodes were positioned either side of the
engineered muscle in order to allow for electric ﬁeld stimulation.
Maximal tetanic force was generated using labVIEW 2012 software
(National Instruments, UK) programmed to deliver a 1 s pulse train at
100Hz and 3.6 v/mm. Data was acquired using a PowerLab 8/35
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(ADInstruments, UK) at a sampling rate of 1 KHz, and was analyzed
with associated LabChart 8 software.
HISTOCHEMISTRY
In order to assess cellular morphology, immediately after functional
testing engineered muscles from normoxic and hypoxic conditions
were ﬁxed by the drop wise addition of ice-cold methanol-acetone
solution. Subsequently constructs were removed from their sutures
and adhered to poly-L-lysine coated microscope slides and ringed
with PAP pen (Sigma–Aldrich) before being permeablized with 1
Tris buffered saline (TBS: 0.5M) and 0.2% Triton x-100 (Fisher
Scientiﬁc, UK) for 2 h. Constructs were then incubated in rhodamine
conjugated phalloidin (Fisher Scientiﬁc) diluted 1:200 in TBS to label
F-actin, and DAPI (Sigma–Aldrich) diluted 1:1000 in order to label
cellular nuclei, and were incubated at room temperature in the dark
for 3 h. Following 4 washes in distilled water, constructs were
mounted on to glass coverslips using a drop of FluoromountTM
medium (Sigma–Aldrich). Images were captured using a Leica
DM2500 Fluorescent microscope at 40  magniﬁcations and
analysis was conducted using Image J software (NIH, USA), with a
minimum of ﬁve images and 40 myotubes analyzed per engineered
muscle.
RNA EXTRACTION AND RT-qPCR
After 24 h of exposure to varying oxygen conditions, constructs
were homogenized in 500ml of TRI Reagent1 (Sigma–Aldrich) using
an electronic stick homogenizer (IKA T10, Fisher Scientiﬁc), and
RNA was extracted thereafter according to the manufacturer’s
instructions. RNA concentration and quality was assessed by UV
spectroscopy at optical densities of 260 and 280 nm using a
Nanodrop 2000 spectrophotometer (Thermo Fisher). Only RNA with
a 260/280 ratio of between 1.8 and 2 was used for RT-qPCR analysis.
mRNA expression of MuRF-1 and MAFbx was determined using
One-step RT-qPCR. Reactions were prepared in transparent 384 well
plates (Applied Biosystems, Thermo Fisher Scientiﬁc, UK), consisting
of 20 ng of RNA in 5ml of nuclease free water, 0.1ml of Quantifast
reverse transcription kit (Qiagen, UK), 0.1ml of both forward
and reverse primers (see Table I, Primers were obtained from
Sigma–Aldrich, UK), and 4.7ml of SYBR Green mix (Qiagen) in order
to create 10mlﬁnal reaction volumes. Plates were then transferred to
a Applied Biosystems Viia 7TM thermal cycler (Applied Biosystems)
which was programmed to perform the following steps: 10min hold
at 50°C (reverse transcription), followed by a 5min hold at
95°C (activation of “hot start” Taq polymerase), and cycling between
95°C for 10 s (denaturation) and 60°C for 30 s (annealing and
extension). Fluorescence was detected after every cycle and data was
analyzed using the 2(DDCT) method making samples relative to one
replicate 21% O2 control sample in each experiment and normalized
to POLR2B levels.
IMMUNOBLOTTING
Following 24h of exposure to varying O2 conditions, MM was
removed from the engineeredmuscle,whichwaswashed twice inPBS,
removed from its sutures, blotted dry and frozen in liquid nitrogen,
and stored at80°Cuntil further analysis. Sampleswere subsequently
homogenized in RIPA lysis buffer (Fisher Scientiﬁc) containing a
protease and phosphatase inhibitor cocktail (Fisher Scientiﬁc) and
rotated for 1 h at 4°C before being centrifuged at 12,000 g in order to
remove insoluble material. The supernatant was transferred to a fresh
tube and protein concentrationswere determined using the Pierce 660
protein assay (Fisher Scientiﬁc). Proteinwasmixedwith a 3X laemmli
buffer and boiled at 95°C for 5 min and equal volumes (10mg) were
loaded in to 8% SDS-polyacrylamide gels and separated at 120V.
Proteins were transferred on to nitrocellulose membranes for 2 h at
0.35A (GE healthcare, Fisher Scientiﬁc) and blocked in 5% BSA at
4°C for 90min. Thereafter, membranes were washed three times in
tris-buffered salineþ 0.1% tween (TBST) and incubatedwith phospho
p70S6 kinaseThr389 (Cell Signalling Technologies, #9234, 1:1000) or
total p70S6 kinase (Cell Signalling Technologies, #2708, 1:2000)
overnight at 4°C. Following three further washes in TBST, membranes
Fig. 1. Experimental time line used to explore the atrophic effects of 24 h of varying oxygen levels in tissue engineered skeletal muscle. Engineered muscle was cultured for 13
days prior to exposure to 21%, 15%, 10%, 5%, or 1% oxygen for a further 24 h at which point muscles were analyzed appropriately.
TABLE I. Primer Sequences Used in This Study for the Detection of E3 Ubiquitin Ligase mRNA
Target mRNA Primer sequence 50-30 Product length NCBI reference sequence
MAFbx F¼GTCGCAGCCAAGAAGAGAA 134 NM_026346.3
R¼CGAGAAGTCCAGTCTGTTGAA
MuRF-1 F¼CCAAGGAGAATAGCCACCAG 67 NM_001039048.2
R¼CGCTCTTCTTCTCGTCCAG
POLR2B F¼GAGAAAGGCTTGGTCAGA 148 NM_153798.2
R¼AATATCTTGGCGGCTCTT
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were incubated for 1 h at room temperature in HRP-conjugated anti-
rabbit IgG secondary antibody (Sigma–Aldrich) diluted 1:1500 in
TBST containing 5% skimmed milk powder before detection with
chemilluminescence. Imaging and band quantiﬁcation were con-
ducted on a ChemiDoc imaging system (Bio-rad, UK) using Quantity
One image software (Version 4.6.8, Bio-rad). Phosphorylation levels
are normalized to total p70S6 kinase and a-tubulin (Cell Signalling
Technologies, #2125, 1:2000) abundance, and are presented as a fold
change compared to a single control (21% O2) sample in each
experiment.
STATISTICAL ANALYSIS
All data are presented as mean SEM. Normality of distribution and
homogeneity of variance in all data sets was determined using a
Shapiro–Wilk test and Levene’s tests, respectively. Data were subse-
quentlyanalyzedusingeitherOne–WayANOVAwithLSDpost-hoc tests
or Kruskall–Wallis tests and Mann–Whitney tests where data were not
normally distributed. All analysiswas conducted using SPSS version 22.
RESULTS
PHYSIOLOGICAL HYPOXIA IMPAIRS MAXIMAL CONTRACTILE FORCE
PRODUCTION
Decreasing levels of O2 signiﬁcantly affected maximal force output
in engineered skeletal muscles (main effect for condition, P< 0.05)
following 24 h of treatment at the end of the culture period. In the
most extreme levels of physiological hypoxia tested, maximal force
production was reduced by 56% and 62% in 1% and 5% O2
conditions, respectively (P< 0.05), compared to ambient (21%)
control muscles (Fig. 2). By contrast, less extreme levels of hypoxia
had a smaller impact on maximal force output, with 10% O2 leading
to a 4% force decrement compared to ambient control muscles
(P¼ 0.626), and 15%O2 associated with a 20% reduction inmaximal
force (P< 0.05, Fig. 2).
REDUCED OXYGEN LEVELS ARE ASSOCIATED WITH MYOTUBE
ATROPHY IN ENGINEERED SKELETAL MUSCLE
Loss of myotube size (diameter) appeared to occur in a dose-dependent
fashion, with more extreme levels of hypoxia associated with
signiﬁcant atrophy (P< 0.05, Fig. 3). Culturing engineered muscles
at 15% O2 had no effect on myotube diameter compared to 21% O2
control muscles (16.92 1.06 vs. 16.80 1.47mm, P¼ 0.938). There
was a small reduction in myotube diameter when engineered muscles
were cultured at 10% O2 (14.47 0.80mm), which although did not
reach statistical signiﬁcance (P¼ 0.14) does represent a 14% reduction
in myotube size compared to control muscles. However, when
engineered muscles were cultured for 24h in either 5%
(12.90 1.50mm) or 1% (13.26 1.36mm) O2, there was a statistically
signiﬁcant reduction inmyotube diameter (P< 0.05)which represented
23% and 21% reductions in myotube size, respectively.
PHYSIOLOGICAL HYPOXIA INCREASES mRNA LEVELS OF MURF-1
AND MAFbx AND DAMPENS PHOSPHORYLATION OF p70S6 KINASE
mRNA levels of the E3 ubiquitin ligases, commonly used as markers of
muscle atrophy/wasting, were elevated by physiological levels of
hypoxia.MuRF-1mRNA (Fig. 4A) expressionwas signiﬁcantly affected
by physiological hypoxia (P< 0.05), with engineered muscle cultured
in 5% (1.330.02) and 1% (1.80 0.33) O2 showing elevated levels
compared to controls in ambient O2 (0.99 0.02, P< 0.05). MAFbx
expression (Fig. 4B) was also signiﬁcantly increased by hypoxia in
engineeredmuscle (P< 0.05), and appeared to be more sensitive to low
O2 levels since its levels were elevated by 10% (1.42 0.07), 5%
(1.55 0.14), and 1% (1.43 0.15) O2 compared with 21% control
muscles (1.04 0.04). Phosphorylation of p70S6k, a downstream
kinase frommTORwas also altered by hypoxia (Fig. 5).While therewas
a step-wise reduction in p70S6 kinase phosphorylation with lower O2
levels, only culture at 1% O2 signiﬁcantly dampened this response
(P< 0.05). No signiﬁcant change in total levels of p70S6 kinase were
observed (P¼ 0.238) although a slight reduction was associated with
more extreme hypoxia (effect size r¼ 0.42).
DISCUSSION
Engineered muscle models closely replicate the physiology and
function of native tissue, however to date there is little data
regarding their ability to replicate muscle from diseases associated
with alterations in muscle phenotype. In this study we aimed to
determine if exposure of engineeredmuscle to hypoxia in vitro could
recreate tissue with similar characteristics to the atrophic muscle
observed in diseases where tissue hypoxia is prevalent in vivo (e.g.,
Fig. 2. Maximal contractile force from engineered muscles cultured for 24 h
at various levels of hypoxia. All hypoxic cultures were compared to 21% O2
control cultures within individual experiments to calculate relative force. Data
are expressed as mean SEM for n¼ 3/4 engineered muscles.  indicates
statistically different to 21% O2 (P 0.05), # indicates signiﬁcantly different
to 15% O2 (P 0.05), C indicates statistically different to 10% (P 0.05).
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COPD). We found that severe loss of muscle force and size were only
associated with the lowest levels of O2 tested, which corresponded
with changes in molecular markers of skeletal muscle loss.
Patients with COPD suffer from a loss of muscle strength of up
to 50% compared with age matched healthy individuals [Mador
and Bozkanat, 2001], and during acute exacerbations of COPD
symptoms, muscle strength is known to further decrease [Gayan-
Ramirez and Decramer, 2013]. While there are likely a number of
factors involved in the worsening of muscle performance (e.g.,
physical inactivity, inﬂammation, use of glucocorticoids); tissue
hypoxia is likely at least partially responsible for this phenomena.
In the present study, we found that acute exposure (24 h) of
engineered muscle to either 1% or 5% O2 resulted in severe
decrements in maximal contractile force generation. Similarly,
myotube size was reduced under these O2 conditions compared to
myotubes cultured under ambient O2 levels, and the loss of muscle
size is also common in COPD sufferers [Mador and Bozkanat,
2001]. In the present study, we cannot discern whether hypoxia
directly causes muscle wasting and impairments in muscle
function, or whether this effect is indirectly mediated through
the impact of hypoxia on other cellular processes (e.g., calcium
handling, oxidative stress etc.); however, this response does closely
match the phenotype observed in skeletal muscle of individuals
with COPD, and particularly that observed during acute exacer-
bations [Gayan-Ramirez and Decramer, 2013].
Elevations in the mRNA levels of the E3 ubiquitin ligases MuRF-1
and MAFbx are common in a number of pathologies associated with
muscle wasting [Gomes et al., 2001; Lecker et al., 2004] as well as
muscle unloading [Bodine et al., 2001]. Furthermore, MuRF-1 and
MAFbx are elevated in skeletal muscle of individuals suffering from
COPD compared to healthy individuals [Lemire et al., 2012] as well as
in rodents exposed to hypoxia for 21 days [de Theije et al., 2013].
Interestingly, we found that MuRF-1 mRNAwas only elevated when
engineered muscles were cultured at 1% O2, and no differences were
seen above this level. By contrast, MAFbx mRNA expression was
signiﬁcantly increased when O2 levels were reduced to 10% or lower
(10%, 5%, and 1%) suggesting that MAFbx is more sensitive to
hypoxia than MuRF-1. Since MuRF-1/MAFbx expression can
regulate muscle breakdown [Bodine et al., 2001], it is reasonable
to suggest that the elevations in these ligases are at least partially
responsible for the myotube atrophy and decrement in muscle
function. Moreover, these data conﬁrm that exposure of engineered
muscle to hypoxia for 24 h activates a molecular pathway known to
induce atrophy in skeletal muscle.
Fig. 3. Myotube diameter in engineered muscles following 24 h of culture at various levels of hypoxia. Data are expressed as mean SEM for n¼ 4 engineered muscles. Scale
bar¼ 20mm.  indicates statistically different to 21% O2 (P 0.05), # indicates statistically different to 15% O2 (P 0.05).
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We also saw that p70S6 kinase phosphorylation (a downstream
effector ofmTORC1)was signiﬁcantlybluntedat 1%O2, suggesting that
the loss of size and strength may be a consequence of decreased
anabolic signaling as well as increased muscle catabolism. The role of
p70S6 kinase in driving cellular hypertrophy iswell deﬁned [Shah et al.,
2000], and it has also recently been shown that this protein kinase is
required for increases in muscle force during hypertrophy [Marabita
et al., 2016]. Furthermore, blunted signaling through the Akt-mTORC1
axishasbeenshown inhypoxia treatedcells [Caronet al., 2009], rodents
[Favier et al., 2010;deTheije et al., 2013], and individuals suffering from
COPD [Favier et al., 2010] as well as myotubes in vitro derived from
COPD muscle [Pomies et al., 2015]. This therefore suggests that the
dampening of p70S6 kinase phosphorylation as a consequence of
hypoxic exposure may in part instigate the loss of myotube size and
muscle force production, and provides more evidence that engineered
muscle exposed to hypoxia in vitro responds in amanner akin to that of
diseased muscle and is comparable to other cell and animal models.
Since native muscle oxygenation lies at approximately 5% O2
[Richardson et al., 2006], 1% represents the only O2 level tested which
would correspond to pathological tissue hypoxia in vivo. However, as
myoblasts are routinely cultured at 21%O2 in vitro, any O2 level below
this may be sensed by the cells as hypoxia and potentially cause
alterations in physiological responses [Deldicque and Francaux, 2013].
It is therefore interesting that only small alterations were observed at
15%or10%O2atboth themolecular andphenotypic level, andsuggests
that 5%O2may represent a threshold atwhichmuscle cells in vitro alter
their homeostasis by reducing muscle size and thus strength. However,
it is noteworthy that the increase in MuRF-1 mRNA expression and
reduction in p70S6 kinase phosphorylation were only apparent at 1%
O2, and therefore pathological levels of hypoxia (1%) may exacerbate
the molecular pathways driving skeletal muscle atrophy.
In summary, the present data suggest that engineered skeletal
muscle exposed to hypoxia responds at both a phenotypic and
molecular level in amanner akin to that observed in skeletalmuscle of
COPD patients. These ﬁndings go some way toward validating the
physiological accuracy of such model systems, and suggest that
engineered muscle may have utility in understanding the underlying
pathophysiology of hypoxia associated muscle dysfunction. Further-
more, we have shown that the atrophy, loss of muscle function, and
molecular responses to hypoxia are most pronounced when
engineered muscle is cultured in O2 levels of 5% (physiological
hypoxia) or less (pathological hypoxia), and thus an in vitro hypoxic
threshold clearly exists for activation of a catabolic cellular response.
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Fig. 4. mRNA expression of E3 ubiquitin ligases following 24 h of culture at
various levels of hypoxia. (A) Muscle Ring Finger-1, and (B) Muscle Atrophy F-
box. Values are normalized to levels of POLR2B and made relative to 21% O2.
Data are expressed as mean SEM from n¼ 4 engineered muscles.  indicates
statistically different to 21%O2 (P 0.05) # indicates statistically different to
15% O2 (P 0.05).
Fig. 5. Phosphorylation of p70S6 kinase following 24 h of culture at various
levels of hypoxia. Phosphorylated p70S6 kinase is normalized to the levels of
total p70S6 kinase anda-tubulin. Data are expressed as mean SEM for n¼ 4
engineered muscles.  indicates statistically different to 21% O2 (P 0.05).
Note that the direction of the western blot is opposite to that of the
representative graph.
JOURNAL OF CELLULAR BIOCHEMISTRY2604 ENGINEERED SKELETAL MUSCLE IN HYPOXIA
REFERENCES
Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou
WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM,
Stitt TN, Yancopoulos GD, Glass DJ. 2001. Identiﬁcation of ubiquitin ligases
required for skeletal muscle atrophy. Science 294:1704–1708.
Caron MA, Theriault ME, Pare MÈ, Maltais F, Debigare R. 2009. Hypoxia
alters contractile protein homeostasis in L6 myotubes. FEBS Lett
583:1528–1534.
Chaillou T, Koulmann N, Meunier A, Pugniere P, McCarthy JJ, Beaudry M,
Bigard X. 2014. Ambient hypoxia enhances the loss of muscle mass after
extensive injury. Pﬂugers Arch Eur J Physiol 466:587–598.
Chakravarthy MV, Spangenburg EE, Booth FW. 2001. Culture in low levels of
oxygen enhances in vitro proliferation potential of satellite cells from old
skeletal muscles. Cell Mol Life Sci 58:1150–1158.
Cheng CS, Davis BNJ, Madden L, Bursac N, Truskey G a. Physiology and
metabolism of tissue-engineered skeletal muscle. Exp Biol Med (Maywood)
239:1203–1214.
de Theije CC, Langen RCJ, Lamers WH, Schols AMWJ, K€ohler SE. 2013.
Distinct responses of protein turnover regulatory pathways in hypoxia- and
semistarvation-induced muscle atrophy. Am J Physiol Lung Cell Mol Physiol
305:L82–L91.
Deldicque L, Francaux M. 2013. Acute vs chronic hypoxia: what are the
consequences for skeletal muscle mass? Cell Mol Exerc Physiol 2:1–23.
Di Carlo A, De Mori R, Martelli F, Pompilio G, Capogrossi MC, Germani A.
2004. Hypoxia inhibits myogenic differentiation through accelerated MyoD
degradation. J Biol Chem 279:16332–16338.
Favier FB, Costes F, Defour A, Bonnefoy R, Lefai E, Bauge S, Peinnequin A,
Benoit H, Freyssenet D. 2010. Downregulation of Akt/mammalian target of
rapamycin pathway in skeletal muscle is associated with increased REDD1
expression in response to chronic hypoxia. Am J Physiol Regul Integr Comp
Physiol 298:R1659–R1666.
Gayan-RamirezG,DecramerM.2013.AcuteexacerbationsofCOPDMechanisms
of striated muscle dysfunction during. J Appl Physiol 114:1291–1299.
Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. 2001. Atrogin-1, a
muscle-speciﬁc F-box protein highly expressed during muscle atrophy. Proc
Natl Acad Sci USA 98:14440–14445.
Khodabukus A, Baar K. 2009. Regulating ﬁbrinolysis to engineer skeletal
muscle from the C2C12 cell line. Tissue Eng Part C Methods 15:501–511.
Khodabukus A, Baar K. 2015. Contractile and metabolic properties of
engineered skeletal muscle derived from slow and fast phenotype mouse
muscle. J Cell Physiol 230:1750–1757.
Khodabukus A, Baehr LM, Bodine SC, Baar K. 2015. Role of contraction
duration in inducing fast-to-slow contractile and metabolic protein and
functional changes in engineered muscle. J Cell Physiol 230:2489–2497.
Kimball SR. 2014. Integration of signals generated by nutrients, hormones,
and exercise in skeletal muscle. Am J Clin Nutr 99:237–242.
Lecker SH, Jagoe RT, Gilbert A, GomesM, Baracos V, Bailey J, Price SR, Mitch
WE, Goldberg AL. 2004. Multiple types of skeletal muscle atrophy involve a
common program of changes in gene expression. FASEB J 18:39–51.
Lemire BB, Debigare R, Dube A, Theriault M, Co^te CH, Maltais F. 2012. MAPK
signaling in the quadriceps of patients with chronic obstructive pulmonary
disease. J Appl Physiol 113:159–166.
Li X, Wang X, Zhang P, Zhu L, Zhao T, Liu S, Wu Y, Chen X, Fan M. 2011.
Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase
pathway is involved in inhibition of myogenic differentiation of myoblasts
by hypoxia. Exp Physiol 972:257–264.
Liu W, Wen Y, Bi P, Lai X, Liu XS, Liu X, Kuang S. 2012. Hypoxia promotes
satellite cell self-renewal and enhances the efﬁciency of myoblast
transplantation. Development 139:2857–2865.
Mador MJ, Bozkanat E. 2001. Skeletal muscle dysfunction in chronic
obstructive pulmonary disease. Respir Res 2:216–224.
Marabita M, Baraldo M, Solagna F, Ceelen JJ, Sartori R, Nolte H, Nemazanyy
I, Pyronnet S, Kruger M, Pende M, Blaauw B. 2016. S6K1 is required for
increasing skeletal muscle force during hypertrophy. Cell Reports
17:501–513.
Martin SD, Collier FM, Kirkland MA, Walder K, Stupka N. 2009. Enhanced
proliferation of human skeletal muscle precursor cells derived from elderly
donors cultured in estimated physiological (5%) oxygen. Cytotechnology
61:93–107.
Martin NRW, Passey SL, Player DJ, Mudera V, Baar K, Greensmith L, LewisM.
2015. Neuromuscular junction formation in tissue engineered skeletal muscle
augments contractile function and improves cytoskeletal organisation.
Tissue Eng 21:2595–2604.
Pomies P, Rodriguez J, Blaquiere M, Sedraoui S, Gouzi F, Carnac G, Laoudj-
Chenivesse D, Mercier J, Prefaut C, Hayot M. 2015. Reduced myotube
diameter, atrophic signalling and elevated oxidative stress in cultured
satellite cells from COPD patients. J Cell Mol Med 19:175–186.
Rahman I, Morrison D, Donaldson K, Macnee W. 1996. Systemic oxidative
stress in asthma, COPD, and smokers. Am J Respir Crit Care Med
154:1055–1060.
Richardson RS, Duteil S, Wary C, Wray DW, Hoff J, Carlier PG. 2006. Human
skeletal muscle intracellular oxygenation: the impact of ambient oxygen
availability. J Physiol 571:415–424.
Shah OJ, Anthony JC, Kimball SR, Jefferson LS. 2000. 4E-BP1 and S6K1:
Translational integration sites for nutritional and hormonal information in
muscle. Am J Physiol Endocrinol Metab 279:E715–E729.
Swallow EB, Reyes D, Hopkinson NS, D-C ManW, Porcher R, Cetti EJ, Moore
AJ, Moxham J, Polkey MI, Swallow EB. 2007. Quadriceps strength predicts
mortality in patients with moderate to severe chronic obstructive pulmonary
disease. Thorax 62:115–120.
Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S,
Tomoike H. 2000. The relationship between chronic hypoxemia and
activation of the tumor necrosis factor-alpha system in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 161:1179–1184.
Vermeeren MA, Schols AM, Wouters EF. 1997. Effects of an acute
exacerbation on nutritional and metabolic proﬁle of patients with COPD.
Eur Respir J 10:2264–2269.
Yun Z, Lin Q, Giaccia AJ. 2005. Adaptivemyogenesis under hypoxia.Mol Cell
Biol 25:3040–3055.
JOURNAL OF CELLULAR BIOCHEMISTRY ENGINEERED SKELETAL MUSCLE IN HYPOXIA 2605
